Gene Biotherapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gene Biotherapeutics Inc.
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Angionetics Inc.
- Cardium Therapeutics, Inc.
- Shanxi Taxus Pharmaceuticals Co., Ltd.
- Shenzhen Forntsea Taxus Industry Capital Management
- Taxus Cardium Pharmaceuticals Group